CN105395676A - Compound medicine composition for treating animal mycotoxicosis - Google Patents
Compound medicine composition for treating animal mycotoxicosis Download PDFInfo
- Publication number
- CN105395676A CN105395676A CN201510711852.6A CN201510711852A CN105395676A CN 105395676 A CN105395676 A CN 105395676A CN 201510711852 A CN201510711852 A CN 201510711852A CN 105395676 A CN105395676 A CN 105395676A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical carrier
- radix
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound medicine composition for treating animal mycotoxicosis. The compound medicine composition contains an effective quantity of plant extract and an effective quantity of matter with the mycotoxin removing effect. The plant extract has the effects of promoting liver and kidney metabolism and protecting liver cells and is selected from schisandra chinensis extract, acanthopanax senticosus extract, liquorice root extract, radix astragali extract, grifola extract, poria cocos extract, rhizoma alismatis extract, plantain herb extract, longhairy antenoron herb extract and Chinese lobelia herb extract. The matter with the mycotoxin removing effect is selected from aluminosilicate, montmorillonite, zeolite, bentonite, hydrated sodium-calcium aluminosilicate, activated carbon, yeast cell walls, micronized cellulose, lactic acid bacteria and a bioconversion agent.
Description
Technical field
The present invention relates to a kind of compound medicament composition for prevention and therapy animal mycotoxin, its active component is made up of plant extract and the material with de-mould effect.
Background technology
The mixed feed of China and the investigation of feedstuff are shown to have the corn sample of 88%, 84%, 77% and 60% respectively containing T-2 toxin, aflatoxin, FT and Ochratoxin A.All corn samples all contain 6-(10-hydroxy-6-oxo-trans-1-undecenyl)-.beta.-resorcylic acid lactone and vomitoxin, and the mixed fodder sample of more than 90% all contains main mycotoxin in above 6.
Conspicuous aspertoxin: the poisoning feature of acute hertz of aspertoxin is nephropathy, enteritis and immunosuppressant, and has an impact to swine reproduction performance, is mainly manifested in the maturation process delaying spermatid, and causes the initial stage motor capacity of sperm to weaken and the lost of life.Be significantly suppress the searching for food of poultry, grow and feather growth on the impact of poultry, cause the decline of egg production and feed conversion rate, cause hatching rate variance and survival rate of embryo to decline.The chickling fertility performance of hatching is also lower than average level, and sexual maturity generally postpones.Conspicuous aspertoxin causes cell in major lymphatic organs (lymphocyte) to degenerate, reduces, and significantly affects the cellular immune level of poultry.
FT: the poisoning meeting of FT causes spike death syndrome or the alimentary toxicosis syndrome of poultry.The symptom of spike death syndrome comprises paralysis, cervical region and extremity abduction, instability of gait, rapid breathing and weightening finish and declines.
Deoxidation Fructus Trichosanthis chain mykol (vomitoxin): vomitoxin is the one in the single-ended spore moldin of modal Fusarium.This gang's toxin causes refusing to eat, vomiting and injury of gastrointestinal tract to pig usually.Because vomitoxin have impact on gastrointestinal tract, cause the absorption of nutrient substance to decline, poor growth, and can cause inflammation and Immunosuppression.The poisoning pig of vomitoxin also shows as the series change of slight nephropathy, atrophy of thyroid gland, gastric mucosa hypertrophy and other blood parameters.
6-(10-hydroxy-6-oxo-trans-1-undecenyl)-.beta.-resorcylic acid lactone: 6-(10-hydroxy-6-oxo-trans-1-undecenyl)-.beta.-resorcylic acid lactone is a kind of metabolite of Fusariumsp, has estrogenic characteristics.After boar contact 6-(10-hydroxy-6-oxo-trans-1-undecenyl)-.beta.-resorcylic acid lactone, foreskin increases, mammary gland enlargement.Its young and middle-aged boar is more responsive than adult male pig, and show as libido and reduce, testis diminishes.Red and swollen and the rectum of vaginal orifice and vaginocele are shown as on the impact of sow pig, in-pig and lactating sow, has obvious detrimental effect to the reproductive performance of sow simultaneously.
T-2 toxin: the sudden change of T-2 toxin energy modificator gene and chromosome damage.Pig is the most responsive to this toxin.Show refusing to eat, vomiting, lose hair or feathers and organize hemorrhage, brood sow then shows as rate of fertilization and reduces, and litter size reduces, weak son and miscarriage.
Aflatoxin: the metabolism of aflatoxin to poultry has wide influence, it can make the enzymatic activity of multiple important digestible starch, protein, fat and nucleic acid decline.Aflatoxin makes the activity index of serum glutamic pyruvic transminase (SGPT), millet straw transferring enzyme (SGOT) and gamma-glutamic acid transferring enzyme (GGT) increase in addition, and prompting liver sustains damage.Broiler aflatoxicosis, the content of gross protein in blood, cholesterol and blood urea nitrogen reduces.Aflatoxin can make that poultry growth is obstructed, feed conversion rate declines, mortality rate increases, egg production reduces, leg disease and ketoboidies pollute.The resistance of environmental stress and pathogenic microorganism is declined.Histopathological examination finds, poultry aflatoxicosis generally all occurs fatty liver, hepatic necrosis and bile duct proliferation.
In sum, mycotoxin can cause Liver and kidney impaired, causes Liver and kidney metabolic detoxification miopragia, causes toxin to accumulate further in vivo, cause the decline of animal immunizing power; Very easily bacterial infection and viral disease, as circovirus infection, reproductive and respiratory syndrome, swine fever, viral diarrhea etc. and and then cause as the secondary infection such as hyperpyrexia disease, mixed infection, cross infection; Finally cause the growth retardation of animal even dead.What the mycotoxin of hormones caused animal in addition breeds decline.
Current solution mycotoxin on the impact of animal mainly by preventing at gastrointestinal adsorption.Kind used on market mainly contains adsorbent class: strain class, the polymer such as aluminosilicate, Montmorillonitum, zeolite, bentonite, hydration sodium calcium aluminosilicate, active carbon, yeast cell wall, micronized fiber element, lactobacillus; Biological transforming agent: antibacterial, fungus, yeast, enzyme etc.Above-mentioned mildew removing agent is all have active function when gastrointestinal tract substantially, for the absorption of Mycotoxins in Feed before can absorbing after digestion and digestion, but any one mildew removing agent all fully and completely can not remove the mycotoxin of all kinds, and the mycotoxin do not removed will be assembled in Liver and kidney.If metabolism the toxin in Liver and kidney can not be fallen as early as possible, toxin buildup will cause the immunity degradation of animal to a certain extent, be easy to infect various antibacterial, virus, then cause that the growth of animal slows down, part impaired mechanical is even dead, carry out great economic loss to cultivation industrial belt.
Summary of the invention
The mechanism of causing a disease based on above mycotoxin and reason; the drug component of this invention adsorbs coefficient principle from the metabolism of promotion Liver and kidney toxin, protection hepatocyte and toxin; reduce mycotoxin residence time in animal body; improve animal autoimmunity simultaneously, reduce mycotoxin to greatest extent to the harm of animal.
The invention provides a kind of compound medicament composition for the treatment of animal mycotoxicosis; the material with de-mould effect of the plant extract containing effective dose and effective dose, wherein said plant extract is have the plant extract promoting Liver and kidney metabolism and the effect of protection hepatocyte.Described plant extract is selected from: Fructus Schisandrae Chinensis extrat, Radix Et Caulis Acanthopanacis Senticosi extract, Radix Glycyrrhizae extract, Radix Astragali extract, polyporus extract, Poria extract, Rhizoma Alismatis extract, Herba Plantaginis extract, Herba Lysimachiae extract, Herba Lobeliae Chinensis extract.
The described material with de-mould effect is selected from: aluminosilicate, Montmorillonitum, zeolite, bentonite, hydration sodium calcium aluminosilicate, active carbon, yeast cell wall, micronized fiber element, lactobacillus, biological transforming agent.Described biological transforming agent is selected from: antibacterial, fungus, yeast, enzyme, functional polymer.
Also containing pharmaceutical carrier in described pharmaceutical composition.Described pharmaceutical carrier comprises diluent as inorganic salts, be selected from calcium carbonate, calcium bicarbonate, calcium sulfate, calcium phosphate, calcium hydrogen phosphate, dalcium biphosphate etc., or solid acids is selected from citric acid, fumaric acid, malic acid, tartaric acid, glycine and maize cob meal, Testa Tritici.
Described pharmaceutical carrier comprises sweeting agent, is selected from: stevioside, sucralose, cyclamate, acesulfame potassium, saccharin sodium, sucrose, fructose, starch sugar, sugar alcohol and oligofructose, isomaltulose, Rhizoma Marantae arundinaceae glucin etc.Be preferably sucralose.
Preferably, described pharmaceutical composition, it is composed as follows:
Fructus Schisandrae Chinensis extrat 40-60g,
Poria extract 70-90g,
Montmorillonitum 500-700g,
All the other are pharmaceutical carrier;
Or,
Fructus Schisandrae Chinensis extrat 40-60g,
Poria extract 70-90g,
All the other are pharmaceutical carrier;
Or,
Herba Lysimachiae extract 20-40g,
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g,
Bacillus subtilis 4000-6000 (hundred million),
All the other are pharmaceutical carrier;
Or
Fructus Schisandrae Chinensis extrat 40-60g,
Radix Glycyrrhizae extract 90-110g,
Beer yeast wall extract 40-60g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 50-70g,
Herba Lobeliae Chinensis extract 90-110g,
Bentonite 400-600g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 50-70g,
Rhizoma Alismatis extract 290-310g,
Lactobacillus 290-310g,
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g
Polyporus extract 110-130g
Lactobacillus 290-310g
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g
Radix Glycyrrhizae extract 90-110g
Mycotoxin mould solution agent 290-310g
All the other are pharmaceutical carrier;
Or
Herba Plantaginis extract 50-70g
Radix Glycyrrhizae extract 90-110g
Hydration sodium calcium aluminosilicate 440-460g
All the other are pharmaceutical carrier;
Particularly preferred pharmaceutical composition, it is composed as follows:
Fructus Schisandrae Chinensis extrat 50g,
Poria extract 80g,
Montmorillonitum 600g,
All the other are pharmaceutical carrier;
Or,
Fructus Schisandrae Chinensis extrat 50g,
Poria extract 80g,
All the other are pharmaceutical carrier;
Or,
Herba Lysimachiae extract 30g,
Radix Et Caulis Acanthopanacis Senticosi extract 60g,
Bacillus subtilis 5000 (hundred million),
All the other are pharmaceutical carrier;
Or
Fructus Schisandrae Chinensis extrat 50g,
Radix Glycyrrhizae extract 100g,
Beer yeast wall extract 50g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 60g,
Herba Lobeliae Chinensis extract 100g,
Bentonite 500g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 60g,
Rhizoma Alismatis extract 300g,
Lactobacillus 300g,
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 60g
Polyporus extract 120g
Lactobacillus 300g
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 60g
Radix Glycyrrhizae extract 100g
Mycotoxin mould solution agent 300g
All the other are pharmaceutical carrier;
Or
Herba Plantaginis extract 60g
Radix Glycyrrhizae extract 100g
Hydration sodium calcium aluminosilicate 450g
All the other are pharmaceutical carrier.
Most preferred pharmaceutical composition, it is composed as follows:
Contain in 1000g:
Plant extract of the present invention, can commercially obtain, and also can prepare according to prior art, as decocted with water by vegetable drug, obtaining extractum, being extract.Extract can be 5-15:1, is preferably 10:1, and namely the vegetable drug of 10 parts of weight extracts the extractum obtaining 1 part of weight, and described extractum is preferably dry extract.
Beneficial effect of the present invention is further illustrated below by way of experimental data:
Field test one:
Certain pig farm of in July, 2012 Hebei China: basic sow 500, is first farrowing sow.Growing and fattening pigs 3000 bull.
Incidence: be mainly manifested on the big porker of body weight more than 70 jin, shows the abnormal enlargement of pudendum outward, and rubescent, with diarrhoea 30% incidence rate, proctoptosis phenomenon often occurs, and insemination of sows rate reduces, and feed intake declines, and poor growth, disease time is about January.Disease Diagnosis of Veterinary is mycotoxicosis.Carry out mycotoxin detection by Semen Maydis with the complete feed that Semen Maydis is worked good, zeranol and vomitoxin severe overweight in result display Semen Maydis, content reaches 1.56mg/kg and 3.12mg/kg respectively.
Therapeutic scheme was as follows at that time: the sick pig of symptom basic simlarity is picked out 200, be divided into two groups, often organize 100, again selected by complete feed the Semen Maydis that mycotoxin contamination is lighter formulated, and matched group and test group mildew removing agent composition component being added in feedstuff respectively, feedstuff per ton adds 1kg respectively.
Matched group composition:
Contain in 1000g compound recipe component:
High-purity Montmorillonitum: 600g
Sucralose: 50g
Diluent is extremely: 1000g
Test group composition (in example one component):
Contain in 1000g compound recipe component:
Usage and dosage is in table one.
Table one
Experimental result is in table two
Conclusion: can finding out eating after by the feedstuff of mycotoxin contamination from experimental result, adding heat-clearing and toxic substances removing in feedstuff, inducing diuresis to remove edema, promote the plant extract of Liver and kidney metabolism, the metabolism of mycotoxin can be promoted, reduce toxin gathering in animal body, rehabilitation after promotion zoosis.
Field test two
Pig farm, Shandong in May, 2012,5000 bull growing and fattening pigs, weight average 40 kilograms, after swinery eats the complete feedstuff by mycotoxin contamination, occur that appetite declines, lassitude, the morbidity later stage, swinery infects haemophilus parasuis, appetite is close to absolutely useless, and liver renal failure, ascites is serious.From sick swinery, select the most serious 60, be divided into two groups, often organize 30, one group is matched group, and one group is test group.With drinking water administration.
Therapeutic scheme is as follows:
Usage and dosage is in table three.
Table three
Experimental result
Experimental result is in table four
Table four
Conclusion: as can be seen from experimental result, washes in a pan swinery to the dead of the secondary infection caused by mycotoxicosis, compares with matched group, and the treatment and the protective effect that are added with the experimental group of Fructus Schisandrae Chinensis extrat and Poria extract have significantly difference and advantage.
Detailed description of the invention
Further illustrate the present invention by the following examples.
Illustrate that the medicine components but be not limited to of this invention exemplifies below:
Contain in example 1.1000g compound recipe component:
Contain in example 2.1000g compound recipe component:
Contain in example 3.1000g compound recipe component:
Contain in example 4.1000g compound recipe component:
Contain in example 5.1000g compound recipe component:
Contain in example 6.1000g compound recipe component:
Contain in example 7.1000g compound recipe component:
Contain in example 8.1000g compound recipe component:
Contain in example 9.1000g compound recipe component:
。
Claims (10)
1. treat the compound medicament composition of animal mycotoxicosis for one kind; it is characterized in that; the material with de-mould effect of the plant extract containing effective dose and effective dose, wherein said plant extract is have the plant extract promoting Liver and kidney metabolism and the effect of protection hepatocyte.
2. pharmaceutical composition according to claim 1, it is characterized in that, described plant extract is selected from: Fructus Schisandrae Chinensis extrat, Radix Et Caulis Acanthopanacis Senticosi extract, Radix Glycyrrhizae extract, Radix Astragali extract, polyporus extract, Poria extract, Rhizoma Alismatis extract, Herba Plantaginis extract, Herba Lysimachiae extract, Herba Lobeliae Chinensis extract.
3. pharmaceutical composition according to claim 1, it is characterized in that, described in there is de-mould effect material be selected from: aluminosilicate, Montmorillonitum, zeolite, bentonite, hydration sodium calcium aluminosilicate, active carbon, yeast cell wall, micronized fiber element, lactobacillus, biological transforming agent.
4. pharmaceutical composition according to claim 1, is characterized in that, described biological transforming agent is selected from: antibacterial, fungus, yeast, enzyme, functional polymer.
5. pharmaceutical composition according to claim 1, is characterized in that, also containing pharmaceutical carrier in described pharmaceutical composition.
6. pharmaceutical composition according to claim 1, it is characterized in that, described pharmaceutical carrier comprises diluent as inorganic salts, be selected from calcium carbonate, calcium bicarbonate, calcium sulfate, calcium phosphate, calcium hydrogen phosphate, dalcium biphosphate etc., or solid acids is selected from citric acid, fumaric acid, malic acid, tartaric acid, glycine and maize cob meal, Testa Tritici.
7. pharmaceutical composition according to claim 1, it is characterized in that, described pharmaceutical carrier comprises sweeting agent, is selected from: stevioside, sucralose, cyclamate, acesulfame potassium, saccharin sodium, sucrose, fructose, starch sugar, sugar alcohol and oligofructose, isomaltulose, Rhizoma Marantae arundinaceae glucin etc.Be preferably sucralose.
8. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition, and it is composed as follows:
Fructus Schisandrae Chinensis extrat 40-60g,
Poria extract 70-90g,
Montmorillonitum 500-700g,
All the other are pharmaceutical carrier;
Or,
Fructus Schisandrae Chinensis extrat 40-60g,
Poria extract 70-90g,
All the other are pharmaceutical carrier;
Or,
Herba Lysimachiae extract 20-40g,
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g,
Bacillus subtilis 4000-6000 (hundred million),
All the other are pharmaceutical carrier;
Or
Fructus Schisandrae Chinensis extrat 40-60g,
Radix Glycyrrhizae extract 90-110g,
Beer yeast wall extract 40-60g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 50-70g,
Herba Lobeliae Chinensis extract 90-110g,
Bentonite 400-600g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 50-70g,
Rhizoma Alismatis extract 290-310g,
Lactobacillus 290-310g,
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g
Polyporus extract 110-130g
Lactobacillus 290-310g
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 50-70g
Radix Glycyrrhizae extract 90-110g
Mycotoxin mould solution agent 290-310g
All the other are pharmaceutical carrier;
Or
Herba Plantaginis extract 50-70g
Radix Glycyrrhizae extract 90-110g
Hydration sodium calcium aluminosilicate 440-460g
All the other are pharmaceutical carrier.
9. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition, and it is composed as follows:
Fructus Schisandrae Chinensis extrat 50g,
Poria extract 80g,
Montmorillonitum 600g,
All the other are pharmaceutical carrier;
Or,
Fructus Schisandrae Chinensis extrat 50g,
Poria extract 80g,
All the other are pharmaceutical carrier;
Or,
Herba Lysimachiae extract 30g,
Radix Et Caulis Acanthopanacis Senticosi extract 60g,
Bacillus subtilis 5000 (hundred million),
All the other are pharmaceutical carrier;
Or
Fructus Schisandrae Chinensis extrat 50g,
Radix Glycyrrhizae extract 100g,
Beer yeast wall extract 50g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 60g,
Herba Lobeliae Chinensis extract 100g,
Bentonite 500g,
All the other are pharmaceutical carrier;
Or
Radix Astragali extract 60g,
Rhizoma Alismatis extract 300g,
Lactobacillus 300g,
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 60g
Polyporus extract 120g
Lactobacillus 300g
All the other are pharmaceutical carrier;
Or
Radix Et Caulis Acanthopanacis Senticosi extract 60g
Radix Glycyrrhizae extract 100g
Mycotoxin mould solution agent 300g
All the other are pharmaceutical carrier;
Or
Herba Plantaginis extract 60g
Radix Glycyrrhizae extract 100g
Hydration sodium calcium aluminosilicate 450g
All the other are pharmaceutical carrier.
10. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition, and it is composed as follows:
Contain in 1000g:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510711852.6A CN105395676B (en) | 2015-10-28 | 2015-10-28 | A kind of compound medicament composition for treating animal mycotoxicosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510711852.6A CN105395676B (en) | 2015-10-28 | 2015-10-28 | A kind of compound medicament composition for treating animal mycotoxicosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105395676A true CN105395676A (en) | 2016-03-16 |
| CN105395676B CN105395676B (en) | 2019-11-08 |
Family
ID=55461671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510711852.6A Active CN105395676B (en) | 2015-10-28 | 2015-10-28 | A kind of compound medicament composition for treating animal mycotoxicosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395676B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106578500A (en) * | 2016-11-16 | 2017-04-26 | 安徽宏亮饲料科技有限公司 | Mycotoxin nosotoxicosis treating nutritional agent for sows and preparation method thereof |
| CN106578382A (en) * | 2016-12-12 | 2017-04-26 | 河北北方牧业科技有限公司 | Mildew-removing compound additive for livestock and poultry |
| CN106721936A (en) * | 2016-11-30 | 2017-05-31 | 广东温氏大华农生物科技有限公司 | A kind of mold toxin sorbent and preparation method thereof |
| CN106819466A (en) * | 2016-12-31 | 2017-06-13 | 安徽宏亮饲料科技有限公司 | The one boar feed addictive of anti-mildew verticillium toxin |
| CN107173540A (en) * | 2017-05-10 | 2017-09-19 | 刘淑鹤 | Release the composite additive of toxin poisoning |
| CN108853343A (en) * | 2018-06-22 | 2018-11-23 | 石家庄石牧动物药业有限公司 | It is a kind of to prevent and treat the Chinese materia medica preparation of chicken mycotoxicosis, preparation method and application |
| CN111011595A (en) * | 2019-08-14 | 2020-04-17 | 长沙创西生物科技有限公司 | Preparation method of compound antidote for livestock and poultry |
| US11096980B2 (en) * | 2016-12-28 | 2021-08-24 | Erber Aktiengesellschaft | Method of using glycyrrhiza plant-based preparation to reduce toxic effect of polypeptide fungitoxin |
| CN114272311A (en) * | 2022-02-21 | 2022-04-05 | 四川农业大学 | Traditional Chinese veterinary medicine composition for treating aflatoxin poisoning |
| CN114522214A (en) * | 2022-01-24 | 2022-05-24 | 河南百动康生物科技有限公司 | Traditional Chinese medicine composition for treating piglet diarrhea and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103583823A (en) * | 2013-11-07 | 2014-02-19 | 北京大北农科技集团股份有限公司 | Mold removal agent for feed and preparation method and feed additive thereof |
-
2015
- 2015-10-28 CN CN201510711852.6A patent/CN105395676B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103583823A (en) * | 2013-11-07 | 2014-02-19 | 北京大北农科技集团股份有限公司 | Mold removal agent for feed and preparation method and feed additive thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106578500A (en) * | 2016-11-16 | 2017-04-26 | 安徽宏亮饲料科技有限公司 | Mycotoxin nosotoxicosis treating nutritional agent for sows and preparation method thereof |
| CN106721936A (en) * | 2016-11-30 | 2017-05-31 | 广东温氏大华农生物科技有限公司 | A kind of mold toxin sorbent and preparation method thereof |
| CN106578382A (en) * | 2016-12-12 | 2017-04-26 | 河北北方牧业科技有限公司 | Mildew-removing compound additive for livestock and poultry |
| CN106578382B (en) * | 2016-12-12 | 2019-12-06 | 河北德润生物科技有限公司 | livestock and poultry mould-removing composite additive |
| US11096980B2 (en) * | 2016-12-28 | 2021-08-24 | Erber Aktiengesellschaft | Method of using glycyrrhiza plant-based preparation to reduce toxic effect of polypeptide fungitoxin |
| CN106819466A (en) * | 2016-12-31 | 2017-06-13 | 安徽宏亮饲料科技有限公司 | The one boar feed addictive of anti-mildew verticillium toxin |
| CN107173540A (en) * | 2017-05-10 | 2017-09-19 | 刘淑鹤 | Release the composite additive of toxin poisoning |
| CN108853343A (en) * | 2018-06-22 | 2018-11-23 | 石家庄石牧动物药业有限公司 | It is a kind of to prevent and treat the Chinese materia medica preparation of chicken mycotoxicosis, preparation method and application |
| CN111011595A (en) * | 2019-08-14 | 2020-04-17 | 长沙创西生物科技有限公司 | Preparation method of compound antidote for livestock and poultry |
| CN114522214A (en) * | 2022-01-24 | 2022-05-24 | 河南百动康生物科技有限公司 | Traditional Chinese medicine composition for treating piglet diarrhea and preparation method thereof |
| CN114272311A (en) * | 2022-02-21 | 2022-04-05 | 四川农业大学 | Traditional Chinese veterinary medicine composition for treating aflatoxin poisoning |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105395676B (en) | 2019-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395676B (en) | A kind of compound medicament composition for treating animal mycotoxicosis | |
| CN101664421B (en) | Traditional Chinese biological preparation for preventing and treating livestock diarrhea and preparation method and feedstuff thereof | |
| CN104543452B (en) | A kind ofly improve feed addictive of sows farrowing ability and preparation method thereof | |
| Van der Meulen et al. | Increasing weaning age of piglets from 4 to 7 weeks reduces stress, increases post-weaning feed intake but does not improve intestinal functionality | |
| CN109770078B (en) | Feed additive for preventing diarrhea of calves in lactation period and using method thereof | |
| CN110100956A (en) | It is a kind of with anti-oxidant and immunoloregulation function " acid+essential oil " coating type feed addictive and its preparation method and application | |
| CN101703171B (en) | Natural vegetal anti-weaning stress feed additive and application thereof | |
| CN108079284B (en) | Medicine for improving sow production performance and preparation method and application thereof | |
| CN105614094A (en) | Fermented-feed raw material preparation special for pregnant sows and preparing method and application thereof | |
| CN105639401A (en) | Feeding mold removal agent formula and application method | |
| CN101869224A (en) | Feed additive for improving lactation performance of lactating sows and preparation method thereof | |
| CN110354139B (en) | Composition for resisting porcine epidemic diarrhea virus infection and application thereof | |
| CN105941918A (en) | Traditional herbal medicine fermenting type lactating sow feed and preparation method thereof | |
| CN103875932A (en) | Functional glycoconjugate for improving sow breeding performance | |
| CN103719623A (en) | Traditional Chinese medicine feed additive capable of preventing or relieving stress syndrome of weaned pigs and preparation method of feed additive | |
| An et al. | Effects of a blend of cinnamaldehyde, eugenol and capsicum oleoresin (CEC) on growth performance, nutrient digestibility, immune response and antioxidant status of growing ewes | |
| CN105941870A (en) | Nanometer montmorillonite feed additive compound for detoxifying and diarrhea prevention of livestock and poultry | |
| Li et al. | Effects of dietary Glycyrrhiza polysaccharide on growth performance, blood parameters and immunity in weaned piglets | |
| CN104431335A (en) | Anti-stress animal feed additive and application thereof | |
| CN103006820A (en) | Chinese medicinal composition with functions of clearing heat and drying dampness and preparation method thereof | |
| Long et al. | Dietary supplementation with Forsythia suspensa extract during late gestation improves reproductive performance, colostrum composition, antioxidant status, immunoglobulin, and inflammatory cytokines in sows and newborn piglets | |
| CN111000905A (en) | Traditional Chinese medicine composition for treating dysentery by using milk, solid fermentation traditional Chinese medicine preparation and preparation method thereof | |
| CN103316272A (en) | Chinese medicinal composition for preventing swine diarrhea | |
| CN109846939A (en) | The fermented tcm extracting solution for preventing and treating piglet bacillary dysentery | |
| CN115645417A (en) | Application of chenodeoxycholic acid in preparation of medicine or feed additive for treating or preventing porcine viral diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |